This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jpids/piad020 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!